Mpox Strain Spreads Locally in U.S.: What You Need to Know

The emergence of locally acquired clade I mpox cases in the U.S. marks a concerning development in the ongoing management of the virus. Clade I, historically found in Central and East Africa, is known for causing more severe illness than clade II, which was responsible for the 2022 global outbreak. The fact that these new cases have no travel history suggests local transmission is occurring, prompting health officials to investigate potential sources of exposure and conduct contact tracing.

The CDC recommends vaccination with the JYNNEOS vaccine for people at high risk of exposure. Early detection, testing, and vaccination are vital to controlling the spread of this virus. Both clade I and clade II may present with flu-like symptoms followed by a rash, with symptoms typically starting within 21 days of exposure. Rashes for clade I tend to cover more of the body, including the face and torso, while rashes from clade II do not always cover the body.

Mpox clade I is a strain of the mpox virus that is associated with more severe illness and higher fatality rates compared to clade II.

Mpox spreads through direct contact with infectious sores or body fluids, sexual or intimate contact, and touching contaminated items such as clothing or bedding.

Symptoms can include rash or sores, fever, chills, sore throat, swollen lymph nodes, and body aches.

Vaccination with the JYNNEOS vaccine is recommended for high-risk individuals. Avoid close contact with people who have mpox, and practice good hygiene.

What are your thoughts on the emergence of this more severe mpox strain? Share this article with others who need to stay ahead of this trend!